Product

Trident: Any antibody. Any payload. Any DAR

Highlights platform flexibility – wildctype mAb input, modular LP kit, tunable DAR. Appeals to BD and scientists alike.

Current platform limitations

Site-specific conjugation made simple and affordable

TRIDENT overcomes all three constraints – no antibody engineering, no glycan clipping, no disulfide shuffling risk, flexible DAR from a single two-step protocol.

How TRIDENT works

TRIDENT is a two-step, enzyme-mediated site specific conjugation platform. Start with any unmodified IgG antibody – no prior engineering required

  1. Input

    WILDTYPE IGG ANTIBODY

    • Any unmodified IgG
    • Any isotype
    • No prior engineering
    • No glycan removal
  2. 01

    ENZYMATIC FUNCTIONALIZATION

    Trident enzyme selectively transfers a click handle bearing linker to a defined set a defined site on the Fc region of the native antibody.

    • Proprietary engineered enzyme
    • Targets conserved Fc site
    • Glycans remain intact
    • Reaction complete in mild aqueous conditions
    • GMP-grade enzyme kit
  3. 02

    CLICK CONJUGATION

    User attaches payload of choice via bioorthogonal click chemistry to the installed handle, completing the ADC in a single, controlled reaction.

    • Compatible with any click-ready payload
    • Use Celltheon off-the-shelf LP kits or your own
    • DAR 2, 4, 6, or 8 – determined by linker structure
    • GLP/GMP-grade LP kits available
  4. Input

    HOMOGENEOUS ADC

    • Defined DAR
    • Native Fc
    • No free drug
    • Narrow DAR distribution
    • Solubility optimized

Key advantages

TRIDENT is the first site-specific conjugation platform to combine native
Fc preservation, zero antibody engineering, and flexible DAR in a single off-the-shelf kit format.

  • No antibody engineering

    Works on any wildtype IgG – no mutagenesis, no sequence modification, no cell line redevelopment. Start conjugating immediately.

  • Native Fc fully intact

    Unlike glycan-clipping platforms, TRIDENT leaves the Fc N-glycan undisturbed. Native effector function, half-life, and FcRn binding are preserved.

  • Flexible DAR: 2, 4, 6, 8

    Stoichiometry-controlled DAR selection from the same platform and kit. No platform switching when payload potency requirements change.

  • Built-in solubility enhancement

    Celltheon’s linker-payloads incorporate a proprietary solubility-enhancing moiety, enabling high-DAR ADCs without aggregation penalties.

  • Off-the-shelf GMP/GLP kits

    Enzyme and linker-payload components available as qualified GMP and GLP kits. No custom synthesis, no lead time for reagents.

  • Simple licensing

    TRIDENT is Celltheon’s proprietary platform offered directly to clients. No third-party licensing burden on your ADC program.

Subtitle

DAR flexibility

Programmable DAR

Select your target drug-to-antibody ratio based on payload potency and indication – determined by linker structure, from a single TRIDENT kit format.

  1. DAR 2 High-potency payloads (e.g., PBDs, calicheamicins)
  2. DAR 4 Standard potency payloads (MMAE, exatecan)
  3. DAR 6 Moderate-potency or bystander-dependent targets
  4. DAR 8 Low-potency payloads needing maximum loading

How to Access TRIDENT

  • TRIDENT kit

    Run it in-house

    • GMP or GLP-grade enzyme + LP kit
    • Protocols, CoA, and tech support included
    • Kits available in research, GLP & GMP grades
    • Run conjugation in your own facility
    • Ideal for labs with conjugation infrastructure
    Scroll
  • Full-Service TRIDENT

    We run it for you

    • Send us your antibody – we handle everything
    • Conjugation + purification + formulation
    • DAR analysis, SE-HPLC, SDS-PAGE included
    • Part of Celltheon’s ADC service packages
    • Seamless handoff to further development stages
    Scroll

Proof Points & Evidence

Data-backed proof of TRIDENT performance

  • Show HIC-HPLC or intact MS trace for DAR 2, 4, 6, and 8
  • Demonstrate narrow DAR distribution vs. random conjugation
  • Key message: homogeneous product, every time
Frequently asked questions

Quick answers
to common questions

Quick answers about timelines, quality, and how to work with Celltheon.

Celltheon builds biotech technology platforms and delivers end-to-end solutions that bridge early drug development and manufacturing.

We support biotech and biopharma teams from discovery through preclinical development and manufacturing readiness.

Our offering spans DNA, protein production, engineering, developability, assays, stable cell lines, conjugation, and process development.

Both. Programs can use an integrated workflow or select the individual services and technologies they need.

Yes. Choose platform transfer to your team or a service model executed by Celltheon scientists.

We begin with your goals, molecule, timeline, and deliverables, then provide a clear technical plan and project scope.

We share relevant case studies, quality documentation, platform data, and a project-specific package aligned with your requirements.

Discuss your molecule with our scientists

We don’t workaround — we innovate
and deliver

Explore whether OmniCHO™ is the right expression platform for your specific protein format.

Talk to a Scientist